GlassScriptPhysician profile
Delfin Santos
NPI 1063420628
$242,219.86
in general payments reported to CMS, 2019-2025
32 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125K · 2020: $59K · 2021: $17K · 2022: $32K · 2023: $9,895 · 2024: $483 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,448 · Food and Beverage: $1,922 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,447.50 |
| Food and Beverage | $1,921.59 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $119,222.04 | 2019 | |
| Amgen INC. | $76,475.92 | 2019-2024 | Otezla, Tavneos, Enbrel |
| Abbvie INC. | $29,852.88 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $7,927.14 | 2019-2023 | |
| Janssen Biotech, INC. | $2,897.96 | 2019-2024 | Tremfya, Simponi Aria |
| Ucb, INC. | $2,394.15 | 2019-2024 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $1,033.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $501.41 | 2019-2024 | |
| Horizon Therapeutics Plc | $262.57 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $257.31 | 2019-2022 | |
| Lilly USA, LLC | $222.52 | 2019-2022 | |
| Genzyme Corporation | $169.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $147.44 | 2019-2024 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.54 | 2019-2023 | Cyltezo |
| Glaxosmithkline, LLC. | $104.75 | 2019-2023 | Benlysta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $103.32 | 2019 | |
| Pacira Therapeutics, INC. | $101.92 | 2019 | |
| Mallinckrodt Hospital Products INC. | $59.33 | 2021-2024 | Acthar |
| Sandoz INC. | $55.46 | 2023-2024 | Hyrimoz |
| Ani Pharmaceuticals, INC. | $44.94 | 2022 | |
| Sobi, INC | $38.56 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $34.35 | 2019-2020 | |
| Organon LLC | $26.89 | 2023 | Renflexis, Hadlima |
| Actelion Pharmaceuticals US, INC. | $25.90 | 2021 | |
| Janssen Scientific Affairs, LLC | $25.74 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.66 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.42 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.39 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.85 | 2021 | |
| Sebela Pharmaceuticals INC. | $11.82 | 2019 | |
| Novo Nordisk INC | $11.62 | 2019 | |
| Biogen, INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delfin Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.